CONSENSUS
Cooperative North Scandinavian Enalapril Survival Study
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 253 patients with NYHA IV heart failure, enalapril reduced 6-month mortality versus placebo.
N
253
Design
Double-blind RCT, terminated early
Endpunkt
Mortality at 6 months
Relevanz
1
Ergebnis26 % vs 44 % (40 % RRR). Effect maintained at 12 months.
CONSENSUS Trial Study Group. N Engl J Med. 1987;316(23):1429-1435. 10.1056/NEJM198706043162301
Diskussion & Kritik
Small but transformative — opened the ACE inhibitor era for HF. Limited to severe HF; SOLVD generalised to milder disease.